Cellectis’ (CLLS) Buy Rating Reiterated at Jefferies Group LLC
Jefferies Group LLC reiterated their buy rating on shares of Cellectis S.A. (NASDAQ:CLLS) in a research note released on Sunday morning. Jefferies Group LLC currently has a $47.00 target price on the biotechnology company’s stock.
Several other analysts also recently commented on CLLS. Zacks Investment Research downgraded Cellectis from a buy rating to a hold rating in a research note on Thursday, August 10th. BidaskClub downgraded Cellectis from a hold rating to a sell rating in a research note on Tuesday, August 1st. SunTrust Banks, Inc. reissued a hold rating and issued a $20.00 price objective on shares of Cellectis in a research note on Friday, October 6th. Nomura lowered their price objective on Cellectis from $49.00 to $43.00 and set a buy rating for the company in a research note on Wednesday, September 6th. Finally, Wells Fargo & Company reissued an outperform rating and issued a $40.00 price objective (up from $33.00) on shares of Cellectis in a research note on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. Cellectis presently has an average rating of Buy and an average price target of $39.50.
Cellectis (CLLS) opened at 35.01 on Friday. The firm has a 50-day moving average price of $29.14 and a 200-day moving average price of $29.04. The company’s market capitalization is $1.26 billion. Cellectis has a 1-year low of $16.09 and a 1-year high of $35.07.
COPYRIGHT VIOLATION WARNING: This article was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://theolympiareport.com/2017/11/01/cellectis-clls-buy-rating-reiterated-at-jefferies-group-llc.html.
Several hedge funds have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. grew its holdings in shares of Cellectis by 27.6% in the second quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock valued at $5,261,000 after acquiring an additional 44,100 shares in the last quarter. Balyasny Asset Management LLC bought a new position in shares of Cellectis in the second quarter valued at approximately $719,000. Eqis Capital Management Inc. grew its holdings in shares of Cellectis by 27.2% in the second quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 2,287 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Cellectis by 132.1% in the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock valued at $247,000 after acquiring an additional 5,435 shares in the last quarter. Finally, Williams Jones & Associates LLC bought a new position in shares of Cellectis in the second quarter valued at approximately $244,000. 14.82% of the stock is owned by institutional investors.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.